BioMarin Pharmaceutical Inc. (BMRN)
| Market Cap | 15.92B |
| Revenue (ttm) | 1.85B |
| Net Income (ttm) | 15.92M |
| Shares Out | 183.59M |
| EPS (ttm) | 0.04 |
| PE Ratio | 2,408.61 |
| Forward PE | 46.95 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 167 |
| Open | 86.83 |
| Previous Close | 90.22 |
| Day's Range | 86.54 - 90.25 |
| 52-Week Range | 71.59 - 92.17 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 116.68 (+34.6%) |
| Earnings Date | Oct 27, 2021 |
About BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is 116.68, which is an increase of 34.56% from the latest price.
News
BioMarin CEO: There are biotech companies 'that probably should not be on the market today'
BioMarin CEO JJ Bienaimé joins Yahoo Finance Live's Julie Hyman and Anjalee Khemlani to discuss the company's first gene therapy product targeted to patients dealing with hemophilia, the future of biote...
BioMarin CEO says study results for hemophilia gene therapy are as 'good as we could hope'
Jean-Jacques Bienaime, CEO and chairman of BioMarin Pharmaceutical, appeared on Tuesday's episode of "Mad Money," discussing trial results for the company's hemophilia gene therapy.
Biomarin plans to resubmit its experimental gene therapy for hemophilia A to the FDA in the second quarter
Shares of BioMarin Pharmaceutical Inc. BMRN, -1.10% gained 5.6% in premarket trading on Monday, the day after the company announced promising data from a Phase 3 clinical study of its investigational ge...
BioMarin's Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe hemophilia A. Annualized Blee...
BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults wi...
SAN RAFAEL, Calif., Jan. 9, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive results from its ongoing global Phase 3 GENEr8-1 study of valoctocogene roxaparvovec...
BioMarin to Participate in Two Virtual Investor Conferences in January
BioMarin to Present at Two Investor Conferences in January 2022 SAN RAFAEL, Calif., Jan. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, C...
BioMarin Update
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioMarin To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Co...
4 Biotechs That Could Be Potential Takeover Targets in 2022
We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attracti...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Lawsu...
NEW YORK, Dec. 22, 2021 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of BioMarin Pharmaceu...
BMRN Final Deadline Today: Rosen, a Longstanding Law Firm, Encourages BioMarin Pharmaceutical Inc. Investors to Secur...
New York, New York--(Newsfile Corp. - December 22, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) bet...
FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in BioMarin Pharmaceutical Inc. with Losses of $100...
LOS ANGELES, Dec. 21, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceutical Inc. ("BioMari...
BMRN FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors to Secure C...
New York, New York--(Newsfile Corp. - December 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) be...
BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular...
SAN RAFAEL, Calif. and SHANGHAI, Dec. 16, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Skyline Therapeutics (formerly Geneception), a gene and cell therapy company focused on dev...
BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors
SAN RAFAEL, Calif., Dec. 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former ...
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors with Losses in Excess of $100K ...
NEW YORK, Dec. 14, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 20...
BioMarin Class Action Reminder
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioMarin To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Co...
BMRN Investor Notice: Rosen, a Global and Leading Law Firm, Encourages BioMarin Pharmaceutical Inc. Investors with Lo...
New York, New York--(Newsfile Corp. - December 9, 2021) - WHY: New York, N.Y., December 9, 2021, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin...
BioMarin Shareholder Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioMarin To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Co...
UPCOMING DEADLINE: BioMarin Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Acti...
San Diego, California--(Newsfile Corp. - December 7, 2021) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of BioMarin Pharmaceutical Inc. of a Class Action Laws...
New York, New York--(Newsfile Corp. - December 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of B...
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Importa...
NEW YORK, Dec. 5, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 202...
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against BioMarin Pharmac...
Los Angeles, California--(Newsfile Corp. - December 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioMarin Pharmaceu...
Rosen, National Trial Lawyers, Encourages BioMarin Pharmaceutical Inc. Investors with Losses to Secure Counsel Before...
New York, New York--(Newsfile Corp. - December 2, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) betw...
BMRN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving BioMarin Pharmaceu...
New York, New York--(Newsfile Corp. - December 2, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased BioMarin Pharmac...
BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 22, 2021 in the Class Action Filed on ...
New York, New York--(Newsfile Corp. - December 2, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: BMR...